Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
This article was originally published in The Pink Sheet Daily
Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
You may also be interested in...
Sanofi’s North American head of pharmaceuticals will move into the top spot at Synta in September, as the company prepares to transition from a clinical-stage to a commercial company. Lead candidate ganetespib has begun Phase III in advanced NSCLC, with final data expected in 2016.
The IPO boom of 2013 is showing signs of slowing, while class of 2012 companies are seeing stock prices decline. Plus news on recent financings by Relypsa, Synta Pharmaceuticals, ArGEN-X and Karyopharm Therapeutics.
If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.